Cochrane · systematic review · CD006190
Colchicine for acute gout
McKenzie, BJ, Wechalekar, MD, Johnston, RV, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
10
No studies
12
Included studies
NR
No studies 12 · 42.9%Ungraded 6 · 21.4%Very low 0 · 0%Low 10 · 35.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyLow‐dose colchicine versus placebo for acute gout
Population: people with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain ‐ not reported Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours Low‐dose colchicine vs placebo | RR 2.43 [1.05, 5.64] | 1 study · 103 participants | Low Downgraded: risk of bias, imprecision |
Reduction of inflammation ‐ not measured Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Function of target joint ‐ not measured Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Serious adverse events Low‐dose colchicine vs placebo | no estimate extracted | 1 study · 133 participants | Ungraded |
Total adverse events Low‐dose colchicine vs placebo | RR 1.32 [0.68, 2.56] | 1 study · 103 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Low‐dose colchicine vs placebo | no estimate extracted | 1 study · 133 participants | Ungraded |
High‐dose colchicine versus placebo for acute gout
Population: people with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain ‐ not reported High‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours High‐dose colchicine vs placebo | RR 2.16 [1.28, 3.65] | 2 studies · 124 participants | Low Downgraded: risk of bias, imprecision |
Reduction of inflammation: proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours High‐dose colchicine vs placebo | RR 10.5 [1.48, 74.38] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Function of target joint ‐ not measured High‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Serious adverse events High‐dose colchicine vs placebo | no estimate extracted | 1 study · 111 participants | Ungraded |
Total adverse events High‐dose colchicine vs placebo | RR 3.21 [2.01, 5.11] | 2 studies · 124 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events High‐dose colchicine vs placebo | no estimate extracted | 1 study · 111 participants | Ungraded |
High‐dose versus low‐dose colchicine for acute gout
Population: people with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain ‐ not reported High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours High‐dose vs low‐dose colchicine | RR 0.87 [0.56, 1.36] | 1 study · 126 participants | Low Downgraded: risk of bias, imprecision |
Reduction of inflammation ‐ not measured High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Function of target joint ‐ not measured High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Serious adverse events High‐dose vs low‐dose colchicine | no estimate extracted | 1 study · 126 participants | Ungraded |
Total adverse events High‐dose vs low‐dose colchicine | RR 2.11 [1.51, 2.95] | 1 study · 126 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events High‐dose vs low‐dose colchicine | no estimate extracted | 1 study · 126 participants | Ungraded |
Low‐dose colchicine versus NSAIDs
Population: people with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain NRS Scale from 0 to 10, 0 is no pain. Low‐dose colchicine vs NSAIDs | no estimate extracted | 1 study · 399 participants | Low Downgraded: risk of bias, imprecision |
Participant global assessment of treatment success: Completely better/much better Low‐dose colchicine vs NSAIDs | RR 0.97 [0.82, 1.15] | 1 study · 399 participants | Low Downgraded: risk of bias, imprecision |
Reduction of inflammation ‐ not measured Low‐dose colchicine vs NSAIDs | no estimate extracted | NR | No studies |
Function of target joint ‐ not measured Low‐dose colchicine vs NSAIDs | no estimate extracted | NR | No studies |
Serious adverse events Low‐dose colchicine vs NSAIDs | no estimate extracted | NR | No studies |
Total number of participants reporting adverse events Low‐dose colchicine vs NSAIDs | RR 1.07 [0.88, 1.29] | 1 study · 399 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Low‐dose colchicine vs NSAIDs | no estimate extracted | NR | No studies |
High‐dose colchicine versus placebo for acute gout
Population: patients with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours High‐dose colchicine vs placebo | RR 2.16 [1.28, 3.65] | 2 studies · 124 participants | Low Downgraded: risk of bias |
Withdrawals due to adverse events ‐ not reported High‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours High‐dose colchicine vs placebo | RR 10.5 [1.48, 74.38] | 1 study · 43 participants | Low |
Function ‐ not measured High‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Participant global assessment ‐ not measured High‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not measured High‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Total adverse events (diarrhoea, vomiting or nausea) High‐dose colchicine vs placebo | RR 3.81 [2.28, 6.38] | 2 studies · 124 participants | Low Downgraded: risk of bias |
Low‐dose colchicine versus placebo for acute gout
Population: patients with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours Low‐dose colchicine vs placebo | RR 2.43 [1.05, 5.64] | 1 study · 103 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events ‐ not reported Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours ‐ not measured Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Function ‐ not measured Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Participant global assessment ‐ not measured Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not measured Low‐dose colchicine vs placebo | no estimate extracted | NR | No studies |
Total adverse events (diarrhoea, vomiting or nausea) Low‐dose colchicine vs placebo | RR 1.24 [0.55, 2.79] | 1 study · 103 participants | Low Downgraded: risk of bias, imprecision |
High‐dose versus low‐dose colchicine for acute gout
Population: patients with acute gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours High‐dose vs low‐dose colchicine | RR 0.87 [0.56, 1.36] | 1 study · 126 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events ‐ not reported High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours ‐ not measured High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Function ‐ not measured High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Participant global assessment ‐ not measured High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Quality of life ‐ not measured High‐dose vs low‐dose colchicine | no estimate extracted | NR | No studies |
Total adverse events (diarrhoea, vomiting or nausea) High‐dose vs low‐dose colchicine | RR 3 [1.98, 4.54] | 1 study · 126 participants | Low Downgraded: risk of bias, imprecision |